Regeneron Pharmaceuticals (LTS:0R2M) Cash per Share: $77.51 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0R2M Regeneron Pharmaceuticals Inc LTS:0R2M
90 GF Score
Price $822.53
GF Value $895.83
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Regeneron Pharmaceuticals Cash per Share?

Regeneron Pharmaceuticals LTS:0R2M -1.61% 90 Cash per Share is $77.51 as of Jun. 2026. GuruFocus rates LTS:0R2M with a GF Score™ of 90/100 and a GF Value™ of $895.83 (Fairly Valued). The stock has 7 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Regeneron Pharmaceuticals's Cash per Share for the quarter that ended in Jun. 2026 was $77.51.

Regeneron Pharmaceuticals  (LTS:0R2M) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Regeneron Pharmaceuticals Cash per Share Related Terms

Regeneron Pharmaceuticals Cash per Share Historical Data

* Premium members only.

The historical data trend for Regeneron Pharmaceuticals's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals Cash per Share Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.40 70.64 99.11 82.22 81.40

Regeneron Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 70.19 80.17 81.40 83.36 77.51
LTS:0R2M
90GF Score
Regeneron Pharmaceuticals Inc LTS:0R2M
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regeneron Pharmaceuticals Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Regeneron Pharmaceuticals's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=8605.2/106
=81.40

Regeneron Pharmaceuticals's Cash per Share for the quarter that ended in Jun. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=7994.6/103
=77.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $77.51 mean?
Regeneron Pharmaceuticals (LTS:0R2M) has a Cash per Share of $77.51 as of Jun. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Regeneron Pharmaceuticals and its competitors.
Is Regeneron Pharmaceuticals' Cash per Share too high?
Regeneron Pharmaceuticals' current Cash per Share is $77.51. Overall, Regeneron Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Cash per Share compare to RVMD and ALNY?
Regeneron Pharmaceuticals' Cash per Share of $77.51 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current Cash per Share is $77.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (LTS:0R2M) is currently considered Fairly Valued. The stock's GF Value™ is $895.83, compared to a current price of $822.53 — trading 8.2% below its estimated fair value. The current Cash per Share is $77.51. Regeneron Pharmaceuticals' overall GF Score™ is 90/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Regeneron Pharmaceuticals (LTS:0R2M), the current Cash per Share is $77.51 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Regeneron Pharmaceuticals (LTS:0R2M) Overvalued in 2026?

Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued. The current stock price of $822.53 is trading 8.2% below its estimated GF Value™ of $895.83. GuruFocus considers Regeneron Pharmaceuticals to be Fairly Valued.

Key valuation signals for LTS:0R2M:

  • Cash per Share: $77.51
  • GF Value™: $895.83 vs. price of $822.53 (8.2% below fair value)
  • GF Score™: 90/100 with 7 warning signs

No single metric tells the full story. See the LTS:0R2M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Regeneron Pharmaceuticals Business Description

Address 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
90GF Score

Get the complete analysis for LTS:0R2M

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$822.53
Price
$895.83
GF Value